Summary
Rats were inoculated s.c. with the Walker 256 solid carcinosarcoma, and when tumors reached a weight of approximately 2–3 g, pharmacokinetics, tissue distribution, and urinary excretion of 195mPt-labelled cisplatin were studied. Cisplatin was given i.v., blood was sampled through arterial cannulae, and data were fitted to a three-compartment model. Distribution half-times were prolonged two- to threefold in tumor-bearing animals, although there was no change in elimination half-time. Initial and steady-state volumes of distribution were also increased in tumor-bearing animals. There was no change in AUC, urinary excretion, tissue distribution, or plasma protein binding. The results indicate that a solid tumor represents an additional compartment for distribution of cisplatin and alters the rate at which cisplatin is distributed from the plasma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barcellona PS, Campana A, Rossi V, Corradino C, Silvestrini B (1984) Comparative study of acute toxicity of drugs used during anticancer therapy in healthy and tumor-bearing mice. Arch toxicol (Suppl) 7:90
Bartosek I, Russo RG, Cattaneo MT (1984) Pharmacokinetics of nitrosoureas: levels of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in organs of normal and Walker 256/B carcinoma bearing rats after i.v. bolus. Tumori 70:491
Benard P, Desplanches D, Macquet JP, Simon J (1983) Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with cisplatin. Cancer Treat Rep 67:457
Benjamin RS (1974) Pharmacokinetics of adriamycin (NSC-123127) in patients with sarcomas. Cancer Chemother Rep (part 1) 58:271
Bonnem EM, Litterst CL, Smith FP (1982) Platinum concentrations in human glioblastoma multiforme following the use of cisplatinum. Cancer Treat Rep 66:1661
Donelli MG, Colombo T, Forgione A, Garattini S (1972) Distribution of 6-mercaptopurine in tumor-bearing animals. Pharmacology 8:311
Harrison SD, Giles HD, Denine EP (1980) Antitumor drug toxicity in tumor-free and tumor-bearing mice. Cancer Chemother Pharmacol 4:199
Knott GD (1981) MLAB: A mathematical modeling tool. Comput Programs Biomed Res 10 (3):271
Lange RC, Spencer RP, Harder HC (1973) The antitumor agent cis-Pt (NH3)2Cl2: distribution studies and dose calculations for 193mPt and 195mPt. J Nucl Med 14:191
Lowenthal IS, Parker LM, Greenblatt DJ, Brown BL, Samy TSA (1979) Pharmacokinetic analysis of neocarzinostatin in normal and tumor-bearing rodents. Cancer Res 39:1547
Nooter K, Sonneveld P, Martens A (1985) Differences in the pharmacokinetics of daunomycin in normal and leukemic rats. Cancer Res 45:4020
Smith PHS, Taylor DM (1974) Distribution and retention of the antitumor agent 195mPt-cisdichlorodiammine platinum (II) in man. J Nucl Med 15:342
Stewart DJ, Leavans M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS (1982) Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42:2472
Villa P, Guaitani A, Bartosek I (1978) Differences in pentobarbital disappearance rate in rats bearing two lines of Walker carcinosarcoma 256. Biochem Pharmacol 27:811
Wolf W, Manaka R (1977) Synthesis and distribution of 195mPt cisdichlorodiammineplatinum (II). J Clin Hematol Oncol 7: 79–95
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Litterst, C.L., Magin, R. Alterations in plasma pharmacokinetics of cisplatin in tumor-bearing rats. Cancer Chemother. Pharmacol. 22, 1–4 (1988). https://doi.org/10.1007/BF00254171
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254171